GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » MedMira Inc (OTCPK:MMIRF) » Definitions » Net Cash per Share

MedMira (MedMira) Net Cash per Share : $-0.02 (As of Jan. 2024)


View and export this data going back to . Start your Free Trial

What is MedMira Net Cash per Share?

Net Cash per Share is calculated as Cash, Cash Equivalents, Marketable Securities minus Total Liabilities minus Minority Interest and then divided by Shares Outstanding (EOP). MedMira's Net Cash per Share for the quarter that ended in Jan. 2024 was $-0.02.

The historical rank and industry rank for MedMira's Net Cash per Share or its related term are showing as below:

MMIRF's Price-to-Net-Cash is not ranked *
in the Biotechnology industry.
Industry Median: 3.96
* Ranked among companies with meaningful Price-to-Net-Cash only.

MedMira Net Cash per Share Historical Data

The historical data trend for MedMira's Net Cash per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MedMira Net Cash per Share Chart

MedMira Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
Net Cash per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.02

MedMira Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
Net Cash per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.02 -0.02 -0.02 -0.02 -0.02

Competitive Comparison of MedMira's Net Cash per Share

For the Biotechnology subindustry, MedMira's Price-to-Net-Cash, along with its competitors' market caps and Price-to-Net-Cash data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MedMira's Price-to-Net-Cash Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, MedMira's Price-to-Net-Cash distribution charts can be found below:

* The bar in red indicates where MedMira's Price-to-Net-Cash falls into.



MedMira Net Cash per Share Calculation

In the calculation of a company's Net Cash per Share, assets other than cash and short term investments are considered to be worth nothing. But the company has to pay its debt and other liabilities in full. This is an extremely conservative way of valuation. Most companies have negative Net Cash per Share. But sometimes a company's price may be lower than its net-cash.

MedMira's Net Cash per Share for the fiscal year that ended in Jul. 2023 is calculated as

Net Cash per Share (A: Jul. 2023 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.01-14.142-0)/697.446
=-0.02

MedMira's Net Cash per Share for the quarter that ended in Jan. 2024 is calculated as

Net Cash per Share (Q: Jan. 2024 )
=(Cash, Cash Equivalents, Marketable Securities-Total Liabilities-Minority Interest)/Shares Outstanding (EOP)
=(0.636-15.307-0)/701.731
=-0.02

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


MedMira  (OTCPK:MMIRF) Net Cash per Share Explanation

Ben Graham invested in situations where the company's stock price was lower than its net-cash. He assigned some value to the company's other current asset. The value is called Net Current Asset Value (NCAV). One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

You can find companies that are traded below their Net Current Asset Value (NCAV) with our Net-Net screener.


MedMira Net Cash per Share Related Terms

Thank you for viewing the detailed overview of MedMira's Net Cash per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


MedMira (MedMira) Business Description

Traded in Other Exchanges
Address
155 Chain Lake Drive, Suite 1, Halifax, NS, CAN, B3S 1B3
MedMira Inc is a biotechnology company that is engaged in the business of research, development, and manufacturing of rapid diagnostics and technologies. The company has one reportable operating segment, rapid diagnostic products and services. The product line of the company includes RevealHIV which detects antibodies to HIV-1 and HIV-2 in whole blood, serum or plasma; H Pylori which detects antibodies in serum, plasma, and whole blood; syphilis which detects treponema pallidum antibodies in serum, plasma, and whole blood; among other products. The company generates revenue geographically from North America, Europe, Asia pacific. The majority of the revenue is generated from North America.

MedMira (MedMira) Headlines

From GuruFocus

MedMira Reports First Quarter Results FY2024

By ACCESSWIRE 12-30-2023

MedMira Closes New Equity Investment for Future Growth

By GlobeNewswire GlobeNewswire 07-15-2021

Management Cease Trade Order Update

By GlobeNewswire GlobeNewswire 12-26-2018

MedMira receives CE mark for its VYRA(TM) CoV2Flu Antigen Test

By ACCESSWIRE ACCESSWIRE 01-11-2023

MedMira Reports Second Quarter Results

By GlobeNewswire GlobeNewswire 03-30-2018

MedMira Reports Third Quarter Results FY2023

By ACCESSWIRE 06-30-2023

MedMira Reports Third Quarter Results

By GlobeNewswire GlobeNewswire 06-30-2018